JP2020111602A5 - - Google Patents

Download PDF

Info

Publication number
JP2020111602A5
JP2020111602A5 JP2020068792A JP2020068792A JP2020111602A5 JP 2020111602 A5 JP2020111602 A5 JP 2020111602A5 JP 2020068792 A JP2020068792 A JP 2020068792A JP 2020068792 A JP2020068792 A JP 2020068792A JP 2020111602 A5 JP2020111602 A5 JP 2020111602A5
Authority
JP
Japan
Prior art keywords
methyl
pyridin
oxy
carbamoyl
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020068792A
Other languages
English (en)
Japanese (ja)
Other versions
JP6985448B2 (ja
JP2020111602A (ja
Filing date
Publication date
Priority claimed from JP2018126337A external-priority patent/JP2018184416A/ja
Application filed filed Critical
Publication of JP2020111602A publication Critical patent/JP2020111602A/ja
Publication of JP2020111602A5 publication Critical patent/JP2020111602A5/ja
Application granted granted Critical
Publication of JP6985448B2 publication Critical patent/JP6985448B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020068792A 2013-03-15 2020-04-07 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体 Active JP6985448B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789971P 2013-03-15 2013-03-15
US61/789,971 2013-03-15
JP2018126337A JP2018184416A (ja) 2013-03-15 2018-07-02 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018126337A Division JP2018184416A (ja) 2013-03-15 2018-07-02 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体

Publications (3)

Publication Number Publication Date
JP2020111602A JP2020111602A (ja) 2020-07-27
JP2020111602A5 true JP2020111602A5 (enExample) 2021-04-22
JP6985448B2 JP6985448B2 (ja) 2021-12-22

Family

ID=51529946

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016503187A Active JP6364472B2 (ja) 2013-03-15 2014-03-14 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体
JP2018126337A Pending JP2018184416A (ja) 2013-03-15 2018-07-02 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体
JP2020068792A Active JP6985448B2 (ja) 2013-03-15 2020-04-07 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016503187A Active JP6364472B2 (ja) 2013-03-15 2014-03-14 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体
JP2018126337A Pending JP2018184416A (ja) 2013-03-15 2018-07-02 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体

Country Status (15)

Country Link
US (1) US9382228B2 (enExample)
EP (1) EP2968287B1 (enExample)
JP (3) JP6364472B2 (enExample)
KR (2) KR102386952B1 (enExample)
CN (3) CN112047927A (enExample)
AU (2) AU2014233414B2 (enExample)
BR (1) BR112015022263B1 (enExample)
CA (1) CA2903288C (enExample)
ES (1) ES2817902T3 (enExample)
IL (2) IL241523B (enExample)
MX (2) MX366429B (enExample)
PH (2) PH12015502336B1 (enExample)
RU (1) RU2769607C2 (enExample)
SG (1) SG11201508532VA (enExample)
WO (1) WO2014145028A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5335056B2 (ja) 2011-11-16 2013-11-06 住友電気工業株式会社 ボルト用アルミニウム合金線及びボルト並びにそれらの製造方法
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CN112047927A (zh) * 2013-03-15 2020-12-08 德西费拉制药有限责任公司 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物
TWI854164B (zh) * 2016-02-01 2024-09-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
KR101691954B1 (ko) * 2016-04-26 2017-01-02 고려대학교 산학협력단 신규 n-아실유레아 유도체 및 이를 함유하는 심혈관질환의 예방 또는 치료용 조성물
KR102374012B1 (ko) 2017-05-24 2022-03-14 아비스코 테라퓨틱스 컴퍼니 리미티드 N-(아자릴)시클로락탐-1-카르복사미드 유도체 및 합성법과 그 용법
CN110461849B (zh) * 2017-06-19 2020-09-01 上海和誉生物医药科技有限公司 一种csf1r抑制剂及其制备方法和应用
KR20200040295A (ko) * 2017-08-24 2020-04-17 메르크 파텐트 게엠베하 보론산 유도체
CN109776401A (zh) * 2017-11-14 2019-05-21 成都博腾药业有限公司 一种制备6-氯-5-三氟甲基-2-氨基吡啶的方法
EP3746059A1 (en) 2018-01-31 2020-12-09 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
WO2019152719A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
CN110845476B (zh) * 2018-08-21 2022-11-18 上海和誉生物医药科技有限公司 一种高选择性csf1r抑制剂、其制备方法和在药学上的应用
EP4303583B1 (en) 2018-12-28 2025-07-23 Deciphera Pharmaceuticals, LLC Csf1r inhibitors for use in treating tenosynovial giant cell tumors
FI3921030T3 (fi) * 2019-02-06 2024-01-08 Lilly Co Eli 1-((2-(2,2,2-trifluorietoksi)pyridin-4-yyli)metyyli)ureajohdannaisia kcnq:n tehostajina
US12509456B2 (en) 2019-03-11 2025-12-30 Deciphera Pharmaceuticals, Llc Solid state forms of ripretinib
CN118930524A (zh) 2019-05-10 2024-11-12 德西费拉制药有限责任公司 苯基氨基嘧啶酰胺自噬抑制剂及其使用方法
SG11202112171XA (en) 2019-05-10 2021-12-30 Deciphera Pharmaceuticals Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
AU2020297422B2 (en) 2019-06-17 2024-03-21 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
DK4084779T3 (da) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc Sammensætninger af 1-(4-brom-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro- 1,6-naphthyridin-3-yl)-2-fluorphenyl)-3-phenylurea
CN119970649A (zh) 2019-12-30 2025-05-13 德西费拉制药有限责任公司 非晶型激酶抑制剂制剂及其使用方法
EP4247795A1 (en) 2020-11-18 2023-09-27 Deciphera Pharmaceuticals, LLC Gcn2 and perk kinase inhibitors and methods of use thereof
WO2022247786A1 (zh) * 2021-05-24 2022-12-01 上海和誉生物医药科技有限公司 一种结晶型csf-1r抑制剂酸式盐及其制备方法和应用
CN115385896B (zh) * 2021-05-24 2024-11-15 上海和誉生物医药科技有限公司 一种csf-1r抑制剂中间体或其酸式盐的制备方法
EP4444429A1 (en) 2021-12-09 2024-10-16 Deciphera Pharmaceuticals, LLC Raf kinase inhibitors and methods of use thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US20250205161A1 (en) 2023-12-08 2025-06-26 Deciphera Pharmaceuticals, Llc Formulations of vimseltinib
WO2025231106A1 (en) 2024-05-01 2025-11-06 Deciphera Pharmaceuticals, Llc Csf-1r inhibitors and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE860511L (en) * 1985-03-01 1986-09-01 Alfa Farmaceutici Spa "Benzoyl urea derivatives having anti-tumor activity"
DE60233736D1 (de) * 2001-06-22 2009-10-29 Kirin Pharma K K Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
ES2364901T3 (es) * 2005-11-15 2011-09-16 Array Biopharma, Inc. Procesos e intermedios para la preparación de derivados de n4-fenil-quinazolin-4-amina.
WO2008046216A1 (en) * 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
WO2008079291A2 (en) * 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CA2742007C (en) * 2008-10-29 2014-07-08 Deciphera Pharmaceuticals, Llc Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
CN112047927A (zh) * 2013-03-15 2020-12-08 德西费拉制药有限责任公司 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物

Similar Documents

Publication Publication Date Title
JP2020111602A5 (enExample)
JP2016516724A5 (enExample)
AU2018236691B2 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
RU2454405C2 (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
CN109071488B (zh) 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂
RU2012126989A (ru) 2-амино-5,5-дифтор-5,6-дигидро-4н-оксазины в качестве ингибиторов васе 1 и(или) васе 2
JP6964576B2 (ja) 置換4−アザインドール及びglun2b受容体調節因子としてのそれらの使用
IL276998B2 (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
JP2017512794A5 (enExample)
JP2009531309A5 (enExample)
JP2016523911A5 (enExample)
JP2010512337A5 (enExample)
JP2015524837A5 (enExample)
RU2016108753A (ru) Ингибиторы ферментов
RU2013125337A (ru) Производные триазола и их применение при неврологических заболеваниях
RU2015100942A (ru) Производное пиперидинилпиразолпиридина
RU2006145205A (ru) Терапевтические соединения: пиридин в качестве каркаса
JP2015514679A5 (enExample)
JP2014527511A5 (enExample)
RU2018131766A (ru) 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета
JP2008509955A5 (enExample)
US20230111910A1 (en) Pd-1/pd-l1 inhibitor, preparation method therefor, and use thereof
RU2013125338A (ru) Производные триазола в качестве лигандов рецепторов гамк
RU2015115360A (ru) Новые анти-инвазивные соединения
JP2020531486A5 (enExample)